Publications by authors named "Marco Torregroza Otero"
Background: In KEYNOTE-355 (NCT02819518), the addition of pembrolizumab to chemotherapy led to statistically significant improvements in progression-free survival and overall survival in patients with advanced triple-negative breast cancer with tumor programmed cell death ligand 1 (PD-L1) combined positive score of at least 10. We report patient-reported outcomes from KEYNOTE-355.
Methods: Patients were randomly assigned 2:1 to pembrolizumab 200 mg or placebo every 3 weeks for up to 35 cycles plus investigator's choice chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin).
Article Synopsis
- The phase 3 trial showed that adding pembrolizumab to chemotherapy improves progression-free survival in patients with advanced triple-negative breast cancer with high PD-L1 expression (CPS of 10 or more).
- In the study, 847 patients were randomly assigned to receive either pembrolizumab plus chemotherapy or a placebo plus chemotherapy, focusing on various PD-L1 expression subgroups.
- Results indicated a significant increase in median overall survival for the CPS-10 subgroup (23.0 months with pembrolizumab vs 16.1 months with placebo), but no significant difference for the lower PD-L1 expressing CPS-1 subgroup.
Background: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.
Methods: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy.